annual meeting program - American Society of Clinical Oncology

FRIDAY
Friday, June 4, 2010
3:30 PM - 4:45 PM
SPECIAL SESSION
ASCO/American Society of Hematology Joint Session
Location: E354a
CME credit: 1.25
Track(s): Special Session
Douglas W. Blayney, MD—Co-Chair
University of Michigan
Hal E. Broxmeyer, PhD—Co-Chair
Indiana University
Mark J. Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FIt3
Mutant AML Patients in First Relapse
Noopur S. Raje, MD
Massachusetts General Hospital Cancer Center
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with
Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
Mathias J. Rummel, MD, PhD
University Hospital Giessen
Bendamustine plus Rituximab Is Superior with Respect to Progression-free Survival and CR
Rate When Compared to CHOP plus Rituximab as First-line Treatment of Patients with
Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized
Phase III Study of the StiL
Peter Borchmann, MD
University Hospital of Cologne
Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (GY) Is the New
Standard of Care in the Treatment of Patients with Early-stage Hodgkin Lymphoma: Final
Analysis of the Randomized German Hodgkin Study Group (GHSH) HD10
74